K. Gary Barnette

Gary Barnette, Ph.D. is the Chief Scientific Officer of the Company. Prior to joining Veru, Dr. Barnette was Sr. Vice President of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services, LLC from 2012 to August 2018 and had responsibility of the oversight and development of scientific and regulatory drug development strategies across virtually all therapeutic areas, including urology, reproductive, oncology, cardiovascular, and analgesics/anesthetics. From 2000 to 2012, Dr. Barnette served in various positions at GTx, Inc. including Vice President, Clinical Development Strategy with responsibilities in regulatory, clinical, and clinical pharmacology in the development of drug products in urology (men’s health) and cancer supportive care. Prior to that, Dr. Barnette was a Clinical Pharmacology and Biopharmaceutics Reviewer at the US FDA, receiving numerous awards for review, mentoring, and serving on various FDA guidance development groups and FDA initiative task forces. Dr. Barnette holds a Ph.D. in Basic Pharmaceutical Sciences (Clinical Pharmacology and Pharmacokinetics) from West Virginia University, School of Pharmacy.